tbuckley/cabot-search huggingface dataset:
Daratumumab, a Novel Human Anti-CD38 Monoclonal antibody shows Anti-Tumor Activity In Mouse Models Of MCL, FL and CLL
Authors: Alba Matas-Céspedes, Anna Vidal Crespo, Vanina Rodriguez, Gael Roue, Armando Lopez-Guillermo, Elias Campo, Dolors Colomer, Jeroen Lammerts van Bueren, Joost M Bakker, Adrian Wiestner, Paul W.H.I. Parren, Patricia Perez-Galan
Journal: Blood (2013)
GW26-e0461 Exosomes secreted from dendritic cells induce angiogenesis by cardiac microvascular endothelial cells after myocardial infarction
Authors: Haibo Liu, Wangjun Yu, Chunming Wang, Xiaofang Guo, Kang Yao, Jie Yuan, Yunzeng Zou, Junbo Ge
Journal: Journal of the American College of Cardiology (2015)
The Role of Hematopoietic Cell Transplantation (HCT) for Burkitt Lymphoma: a Report From the Center for International Blood and Marrow Transplant Research (CIBMTR)
Authors: James L. Gajewski, Jeanette Carreras, Hillard M. Lazarus, Ginna G. Laport, Silvia Montoto, David G. Maloney, Parameswaran Hari
Journal: Blood (2010)
Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
Authors: Irene M. Ghobrial, Kenneth H. Shain, Jacob Laubach, Patrick Henrick, James Vredenburg, Pamela Crilley, Michael Constantine, Caroline Block, Frank G. Basile, Joseph Cappuccio, Abdel Kareem Azab, Emily Lai, Aaron Caola, Ranjit Banwait, Alexandra Savell, Nikhil C. Munshi, Claudia E. Paba-Prada, Robert L. Schlossman, Stacey Chuma, Kimberly Noonan, Kenneth C. Anderson, Paul G. Richardson
Journal: Blood (2015)
CD32B on Clonal Plasma Cells in Systemic Light-Chain Amyloidosis (AL) and Multiple Myeloma (MM): A Target for Immunotherapy in Both Disorders and a Prognostic Marker in MM.
Authors: Adam Boruchov, P. Zhou, A. Olshen, C. Rankin, E. Bonvini, S. Koenig, M. Fleisher, R. Rose, S. McKenzie, Peter Maslak, Suresh C. Jhanwar, James W. Young, Stephen D. Nimer, Raymond Comenzo
Journal: Blood (2006)
Salvianolic acid A alleviates renal injury in systemic lupus erythematosus induced by pristane in BALB/c mice
Authors: Yihuang Lin, Yu Yan, Huifang Zhang, Yucai Chen, Yangyang He, Shoubao Wang, Lianhua Fang, Yang Lv, Guanhua Du
Journal: Acta Pharmaceutica Sinica B (2016)

The purpose of this study was to investigate the effects of salvianolic acid A (SAA) in systemic lupus erythematosus (SLE) induced by pristane in BALB/c mice. Lupus mice were established by confirming elevated levels of autoantibodies and IL-6 after intraperitoneal injection of pristane. Mice were then treated with daily oral doses of SAA for 5 months in parallel with mice treated with prednisone and aspirin as positive controls. The levels of autoantibodies were monitored at monthly intervals and nephritic symptoms observed by hematoxylin and eosin (H&E) and periodic acid–Schiff (PAS) staining. Western blot analysis of renal tissue was also employed. SAA treatment caused a significant reduction in the levels of anti-Sm autoantibodies and reduced renal histopathological changes and pathological effects. SAA treatment also significantly inhibited the phosphorylation of IKK, IκB and NFκB in renal tissues of lupus mice. In conclusion, the results suggest that SAA alleviates renal injury in pristane-induced SLE in BALB/c mice through inhibition of phosphorylation of IKK, IκB and NFκB.
Aminoglycoside-induced deafness in leukemic patients: Cost-effectiveness of prevention by genetic testing
Authors: M. Bitner-Glindzicz, V. Osei-Lah, I. Colvin, T. Sirimanna, D. Lucas, B. MacArdle, D. Webb, A. Shankar, J. Kingston, L. Jenkins, S. Rahman
Journal: Journal of Clinical Oncology (2007)

9014 Background: Aminoglycosides are highly-effective, inexpensive antimicrobials widely used in empirical combination therapy for fever in children with severe neutropenia, including patients receiving treatment for acute leukemia. Some genetically predisposed individuals are exquisitely sensitive to the cochleotoxic effects of these drugs, even when levels are within the therapeutic range. This genetic susceptibility is maternally inherited and caused by mutation of the MT-RNR1 gene encoding mitochondrial 12S rRNA at base position 1555, termed m.1555A&gt;G. Methods: Retrospective analysis of m.1555A&gt;G positive cases in the Regional Diagnostic laboratory to determine how many were revealed by aminoglycoside treatment for cancer treatment-related sepsis. Results: Three unrelated mutation positive individuals were identified in a two year period. All were children with acute lymphoblastic leukemia who experienced rapidly progressive hearing loss during their treatment. Two of the three children have a post-lingual hearing loss of sufficient severity to merit cochlear implantation. None had a significant family history of deafness. Conclusions: Initial estimates of the prevalence of the m.1555A&gt;G mutation were based upon extrapolation back from its contribution to the cause of hearing loss amongst hearing-impaired people and were thought to be low. However, recent small studies of the prevalence of m.1555A&gt;G in the general population suggest that prevalence is much higher than previously calculated (1 in 206 in New Zealand (n=206), 1 in 1,161 in Texas (n=1,161)) but that penetrance, at least in the absence of aminoglycosides, is low. Using estimates of the lifetime cost of pediatric cochlear implantation we suggest that screening for the m.1555A&gt;G mutation at the time of diagnosis of leukemia would be cost effective and therefore suggest that all children diagnosed with leukemia should be screened for this mutation prior to receiving aminoglycoside therapy. No significant financial relationships to disclose.
The usefulness of positron emission tomography (PET) scanning to identify early recurrent melanoma in high risk resected stage III and IV patients: A retrospective review
Authors: L. A. Kottschade, V. Lowe, S. N. Markovic
Journal: Journal of Clinical Oncology (2007)

8566 Background: The incidence of malignant melanoma has risen dramatically over the past decades. Prognosis for patients with metastatic melanoma is poor and treatment options are limited. Complete surgical resection is frequently front line therapy for patients with resectable metastases. However this is only an option if relapse is diagnosed early. PET imaging using 2-flourine-18, 2-fluro-2-deoxy-D-glucose (FDG) has been used successfully for staging of metastatic melanoma. However it's usefulness in surveillance for patients at high-risk of relapse (resected stage III and IV disease) has not been well studied. We conducted a retrospective review of our institutional experience using PET scanning as part of regular follow up in patients with resected stage III or IV melanoma for the purpose of detection of early recurrence. Methods: Retrospective review of the medical records of 667 consecutive patients seen at Mayo Clinic from 12/13/1999–1/1/2007, with the diagnosis of malignant melanoma for whom PET imaging was performed or reviewed at our institution. Eligibility criteria included: resected stage III or IV melanoma with at least 2 PET scans (&lt;1 year apart) as part of regular clinical follow-up (surveillance). Frequency of PET scanning was variable and at physician discretion. Results: Of the 667 patients, 110 patients were deemed eligible for review. There were 98 recurrences among 65 patients. Of these 37 recurrences (38%) were found by PET scanning alone (asymptomatic); 61 recurrences (62%) were found by other methods (physical exam, CT, MRI, etc). Of the 37 recurrences found by routine PET scanning 17 (46%) were completely resected; of the other 61 recurrences found by other methods 33 (54%) were completely resected. Conclusions: PET scanning as regular surveillance for patients with high risk melanoma, may be a useful tool in early identification of asymptomatic melanoma relapse amenable to complete surgical resection (additional 1/3 of cases). Considering the potential clinical benefit of completely resected melanoma relapse, and the retrospective nature of this review, these data are hypothesis-generating and warrant further investigation. No significant financial relationships to disclose.
The Campath-Level at the Day of Transplant Predicts T-Cell Engraftment after Allogeneic Stem Cell Transplantation.
Authors: Johannes Schetelig, Christian Thiede, Martin Bornhaeuser, Brigitte Mohr, Uta Oelschlägel, Gabi Geissler, Rainer Schwerdtfeger, Herrad Baurmann, Alexander Kiani, Uwe Platzbecker, Wolfgang Siegert, Gerhard Ehninger
Journal: Blood (2006)
Survival benefit of switching to anastrozole after 2 years’ treatment with tamoxifen versus continued tamoxifen therapy: The ARNO 95 study
Authors: M. Kaufmann, W. Jonat, J. Hilfrich, H. Eidtmann, G. Gademann, I. Zuna, G. Von Minckwitz
Journal: Journal of Clinical Oncology (2006)

547 Background: Initial adjuvant treatment with anastrozole has significant efficacy and tolerability advantages over tamoxifen in postmenopausal women with hormone-sensitive early breast cancer (EBC) (ATAC Trialists’ Group. Lancet 2005; 365: 60–62). The ARNO 95 study evaluated prospectively switching to anastrozole from tamoxifen after 2 years, compared with continuing tamoxifen therapy. Here, we present an interim efficacy and safety analysis. Methods: This was a prospective, randomized, open-label study conducted in 54 centers in Germany. Postmenopausal women (≤75 years) with hormone receptor-positive, invasive EBC, who had received 2 years of adjuvant tamoxifen without recurrence, were randomized to switch to anastrozole (1 mg/day) or continue on tamoxifen (20 or 30 mg/day) for a further 3 years. No adjuvant chemotherapy was given. The primary end point was disease-free survival (DFS; time to earliest occurrence of local or distant recurrence, new primary breast cancer, or death from any cause); secondary end points included overall survival (OS), safety, and tolerability. Data were analyzed using a log-rank test; a second analysis used a Cox proportional hazards model with covariates of age, tumor size, nodal status, grade, and type of surgery. Results: Overall, 979 patients (mean age 60 years; 74% node-negative; 97% hormone receptor-positive) were enrolled, 489 were randomized to switch to anastrozole, with 490 continuing on tamoxifen. Median follow-up was 30.1 months. Switching to anastrozole significantly improved DFS and OS compared with continuing on tamoxifen ( Table ). Fewer patients who switched to anastrozole reported serious adverse events (22.7%) compared with those who remained on tamoxifen (30.8%). Conclusions: Switching endocrine treatment improved DFS and OS in this well-defined population. Postmenopausal women with hormone-sensitive EBC who have already received 2 years’ adjuvant tamoxifen therapy should be switched to anastrozole. [Table: see text] [Table: see text]
Relationship Between Lenalidomide Dose Modification and Outcomes in Patients with Myelodysplastic Syndromes
Authors: Amy E. DeZern, Gary Binder, Albert Fliss, X. Henry Hu, Syed Rizvi, Frank A. Corvino, Steven R. Arikian, Andy Surinach, Jianyi Lee, B. Douglas Smith
Journal: Blood (2015)
Host Nrf2 –glutathione Redox Dysregulation Precedes TNF-α Elevation and Predicts Severity of Graft Versus Host Disease in Experimental Transplantation
Authors: Jung H Suh, Bindu Kanathezhath, Shenvi Swapna, Hua Guo, Mark C. Walters, Bruce N. Ames
Journal: Blood (2012)
Looking for new targets for prostate cancer therapy: Nuclear factor kappa B and CXCR4 co-expression in prostate specimens from RTOG-8610
Authors: E. D. Bernstein, K. Bae, L. A. Baldridge, S. Zhang, L. Cheng, H. Wolkov, M. Pilepich, A. P. Dicker, C. J. Sweeney
Journal: Journal of Clinical Oncology (2006)

14578 Background: The transcription factor Nuclear Factor-kappa B (NFκB) promotes the production of angiogenic, anti-apoptotic and prometastatic factors that are involved in carcinogenesis. The chemokine receptor CXCR4, which is under the control of NFκB, has been implicated in regulating metastasis of breast, pancreatic, and prostate cancer. This retrospective cohort study evaluated the frequency and co-expression of NFκB and CXCR4 in human prostate cancer specimens. Methods: Paraffin embedded samples from a subset of patients in the RTOG 8610 trial underwent immunohistochemical staining for NFκB and CXCR4. This study compared radiotherapy plus hormonal therapy to radiation therapy alone. The amount of NFκB and CXCR4 was scored by a blinded pathologist for the percentage of cells stained (0 to 100%) and staining intensity (0 to 3+). Results: NFκB and CXCR4 status was determined for 55 and 63 patients, respectively. Both NFκB and CXCR4 status were available for 51 of these patients. Of these, 51% were 2/3+ for NFκB and 61% were 2/3+ for CXCR4. There was a trend towards correlation between CXCR4 and NFκB staining as 18 of the 36 patients who were 2/3+ positive for NFκB were 2/3+ for CXCR4. 10 of the 11 pts with 3+ NFκB had 2/3+ CXCR4. This was consistent with the understanding that CXCR4 is regulated by NFκB, but did not reach statistical significance (p = 0.1298). Neither NFκB or CXCR4 were statistically significantly prognostic factors in this small subset of patients. Conclusion: NFκB and CXCR4 are expressed in a significant number of patients with organ confined prostate cancer. Neither predicted outcomes in this analysis, which may be due to the small sample size. This data supports the notion that NFκB regulates CXCR4 expression in prostate cancer and that one or both may be potential new targets for therapeutic intervention. Studies in larger prospective studies to determine the utility of NFκB and CXCR4 as predictive biomarkers and/or therapeutic targets is warranted. [Table: see text] No significant financial relationships to disclose.
Quantitative T2*MRI for Bone Marrow Iron Overload Assessment in Thalassemia Major and Intemedia Patients
Authors: Antonella Meloni, Roberta Renni, Nicola Romano, Carla Cirotto, Francesco Gagliardotto, Maurizio Caniglia, Lucia De Franceschi, Maria Giovanna Neri, Vincenzo Positano, Gianluca Valeri, Gennaro Restaino, Massimiliano Missere, Alessia Pepe
Journal: Blood (2014)
Identification of MDS-Specific and Methylation Associated Downregulation of Survivine and WT1 in Highly Purified Hematopoietic Progenitor Cells during In Vitro Lineage Specific Differentiation.
Authors: Olaf J. Hopfer, Martina Komor, Dieter Hoelzer, Eckhard Thiel, Wolf-Karsten Hofmann
Journal: Blood (2005)
A Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm: A Study from the AGIMM Group
Authors: Lisa Pieri, Chiara Paoli, Umberto Arena, Fabio Marra, Alessandro Castellani, Stefano Colagrande, Fabio Mori, Arianna Masciulli, Silvia Betti, Vittorio Rosti, Ilaria Nichele, Guido Finazzi, Maria Luisa Ferrari, Elisa Rumi, Paola Guglielmelli, Rajmonda Fjerza, Carmela Mannarelli, Tiziana Fanelli, Alberto Bosi, Giuseppe Cimino, Francesco Passamonti, Valerio De Stefano, Marco Ruggeri, Mario Cazzola, Alessandro Rambaldi, Tiziano Barbui, Giovanni Barosi, Alessandro Maria Vannucchi
Journal: Blood (2014)
Macrophage Epithelial Reprogramming Underlies Mycobacterial Granuloma Formation and Promotes Infection
Authors: Mark R. Cronan, Rebecca W. Beerman, Allison F. Rosenberg, Joseph W. Saelens, Matthew G. Johnson, Stefan H. Oehlers, Dana M. Sisk, Kristen L. Jurcic Smith, Neil A. Medvitz, Sara E. Miller, Le A. Trinh, Scott E. Fraser, John F. Madden, Joanne Turner, Jason E. Stout, Sunhee Lee, David M. Tobin
Journal: Immunity (2016)
Evidence for improved pathologic complete response (PCR) rate after preoperative chemoradiotherapy with 5-FU/oxaliplatin (5FU/OX) for rectal cancer
Authors: C. M. Dolinsky, N. N. Mahmoud, R. Mick, W. Sun, R. W. Whittington, L. J. Solin, D. G. Haller, B. J. Giantonio, P. J. O’Dwyer, R. D. Fry, J. M. Metz
Journal: Journal of Clinical Oncology (2006)

3567 Background: The use of preoperative chemoradiotherapy (chemo/RT) with 5-FU for locally advanced rectal cancer has increased dramatically. The addition of oxaliplatin (OX) to preoperative 5-FU may be a more active regimen than 5-FU alone. This retrospective study was undertaken to describe clinical outcomes in patients (pts) with rectal cancer treated with 5FU/OX or 5-FU alone. Methods: Between 11/90 and 4/05, 114 pts with rectal adenocarcinoma underwent preoperative chemo/RT at the University of Pennsylvania. Chemotherapy consisted of 5FU/OX in 36 (32%) pts and 78 (68%) pts received 5-FU. All pts received preoperative RT (median dose 5040 cGy). The two groups were balanced in terms of demographic and tumor related factors including tumor size, stage and distance from the anal verge. Median follow-up from preoperative chemo/RT was 24 months (range 2–125 months). A total of 105 (92%) pts had surgical resections; 61 (58%) with LAR, 44 (42%) with APR. PCR was defined as either no evidence of viable malignant cells in specimen or scattered, isolated malignant cells without gross residual disease. Non-surgical pts were counted as treatment failures. Results: The PCR rate was 36.1% (95% CI 20.4–51.8%) in 5FU/OX pts and 12.8% (95% CI 5.4–20.2%) in 5-FU pts. The probability of observing 13 PCRs in 36 5FU/OX pts if the actual PCR rate was 15% is equal to 0.001. Rates of any grade III/IV toxicity were similar between each regimen (20% 5FU/OX vs. 17% 5FU). Long term outcomes (2yr rate±SE) of local control, freedom from distant failure and progression-free survival in 23 pts who achieved a PCR were: 100%, 94%±6% and 94%±6%, respectively. In 85 pts with gross residual disease, these rates were: 87%±5, 77%±5% and 71%±6%, respectively. Conclusion: In this retrospective study, patients receiving 5FU/OX with radiation had a higher rate of PCR than those receiving 5FU alone. Overall, a PCR may lead to improved long-term outcomes. A prospective randomized trial to test superiority of the 5FU/OX regimen is warranted. [Table: see text]
GW26-e4470 Effect of Aconine on the expression of Sirt-1 and eNOS system in EAhy926 cell injured by Homocysteine
Authors: Yong Liu, Zhenda Zheng, Bin Zhou, Baoshun Hao, Shujie Yu, Dinghui Liu, Zhiming Song, Lin Wu, Min Wang, Ximei Zhang, Lin Chen, Xiaoxian Qian
Journal: Journal of the American College of Cardiology (2015)
Short-term Effects of High-Dose Caffeine on Cardiac Arrhythmias in Patients With Heart Failure
Authors: Priccila Zuchinali, Gabriela C. Souza, Maurício Pimentel, Diego Chemello, André Zimerman, Vanessa Giaretta, Joyce Salamoni, Bianca Fracasso, Leandro I. Zimerman, Luis E. Rohde
Journal: JAMA Internal Medicine (2016)

The presumed proarrhythmic action of caffeine is controversial. Few studies have assessed the effect of high doses of caffeine in patients with heart failure due to left ventricular systolic dysfunction at high risk for ventricular arrhythmias.To compare the effect of high-dose caffeine or placebo on the frequency of supraventricular and ventricular arrhythmias, both at rest and during a symptom-limited exercise test.Double-blinded randomized clinical trial with a crossover design conducted at the heart failure and cardiac transplant clinic of a tertiary-care university hospital. The trial included patients with chronic heart failure with moderate-to-severe systolic dysfunction (left ventricular ejection fraction <45%) and New York Heart Association functional class I to III between March 5, 2013, and October 2, 2015.Caffeine (100 mg) or lactose capsules, in addition to 5 doses of 100 mL decaffeinated coffee at 1-hour intervals, for a total of 500 mg of caffeine or placebo during a 5-hour protocol. After a 1-week washout period, the protocol was repeated.Number and percentage of ventricular and supraventricular premature beats assessed by continuous electrocardiographic monitoring.We enrolled 51 patients (37 [74%] male; mean [SD] age, 60.6 [10.9] years) with predominantly moderate-to-severe left ventricular systolic dysfunction (mean [SD] left ventricular ejection fraction, 29% [7%]); 31 [61%] had an implantable cardioverter-defibrillator device. No significant differences between the caffeine and placebo groups were observed in the number of ventricular (185 vs 239 beats, respectively; P = .47) and supraventricular premature beats (6 vs 6 beats, respectively; P = .44), as well as in couplets, bigeminal cycles, or nonsustained tachycardia during continuous electrocardiographic monitoring. Exercise test-derived variables, such as ventricular and supraventricular premature beats, duration of exercise, estimated peak oxygen consumption, and heart rate, were not influenced by caffeine ingestion. We observed no increases in ventricular premature beats (91 vs 223 vs 207 beats, respectively) in patients with higher levels of plasma caffeine concentration compared with lower plasma levels (P = .91) or with the placebo group (P = .74).Acute ingestion of high doses of caffeine did not induce arrhythmias in patients with systolic heart failure and at high risk for ventricular arrhythmias.clinicaltrials.gov Identifier: NCT02045992.
Inventaire des ressources et des moyens de contrôle des maladies transmissibles dans l'Union Européenne
Authors: S Salmaso
Journal: Eurosurveillance (1998)

L’Istituto Superiore di Sanita (ISS) a Rome, en collaboration avec le Public Health Laboratory Service (PHLS) a Londres et le Swedish Institute for Infectious Diseases Control (SIIDC) a Stockholm, conduit une analyse scientifique et technique des moyens existants pour le controle des maladies transmissibles dans l’Union Europeenne.
Antiviral treatment in Hepatitis C Virus (HCV)- related low grade non-Hodgkin lymphoma: An update of a multicenter study
Authors: D. Vallisa, P. Bernuzzi, A. Lazzaro, E. Trabacchi, A. Arcari, C. F. Moroni, R. Bertè, P. Mordenti, L. Cavanna
Journal: Journal of Clinical Oncology (2006)

17526 Background: HCV is largely diffuse in North-western Europe and U.S.A. It has been shown to play a role both in hepatocellular carcinoma and in B-cell non-Hodgkin lymphoma (B-NHL). Up to now the exact biological mechanisms that could explain the lymphomagenic role of the virus are under study. Methods: We have previously published a series of 13 patients, affected by low grade B-cell NHL and characterized by an indolent course (i.e. doubling time less than 1 year, no bulky disease), who underwent antiviral treatment only with peghilated interferon and ribavirin (peghilated interferon 50–70 microgram weekly, ribavirin 1000–1200 mg daily). Now we report the second update of this study. Up to now 17 patients are evaluable with a mean follow up of 12.1 ± 8 months (range 2–31 months). Results: Eight patients experienced complete or good partial haematological response that has lasted up to now with a mean follow up of 19,5 months, among them 3 splenic marginal lymphomas, 2 nodal marginal, 1 follicular lymphoma, 1 plasmocytoid and 1 marginal extranodal lymphoma. Three other patients achieved a long lasting partial response. The only one relapse (marginal nodal lymphoma) occurred about one year after the end of treatment, hematological relapse happened together with viral relapse, the lymphoma reappeared as highly chemo resistant high grade lymphoma, and two months later the patient died. Interestingly complete and good partial responses were more likely to be seen in viral genotype 2 (p = 0.04) and were strictly related to the decrease of viral load under treatment (p = 0.005). Toxicity causes the stop of the treatment in 3 patients; however one of them was able to achieve complete hematological response. Time to achieve hematological response was quite long (mean 8 ± 4.5 months). Conclusions: This kind of experience strongly provides a role for antiviral treatment in patients affected by HCV related low grade B-cell NHL. Especially viral genotype 2 infection may be considered a good prognostic marker for hematological response as well as decrease of viral load under treatment. Toxicity in our hands was however significant and further experiences are warranted in order to better modulate antiviral therapy doses. No significant financial relationships to disclose.